



INTERVENTIONAL ONCOLOGY REIMBURSEMENT POLICY ALERT

2022 MEDICARE PHYSICIAN FEE SCHEDULE (MPFS) FINAL RULE

November 2, 2021, the Centers for Medicare and Medicaid Service (CMS) released the calendar year (CY) Medicare's Physician Fee Schedule (MPFS). The payment rate updates are relevant to Medicare beneficiaries treated in the physician office or Office-Based Lab (OBL) setting. The payment rates are effective for service performed on or after January 1, 2022.

Below you will find policy highlights of relevance to the Peripheral Interventions Interventional Oncology product portfolio. A detailed summary of the MPFS will follow.

POLICY HIGHLIGHTS

CMS finalized a nearly 4% reduction to the Conversion Factor, from \$34.89 to \$33.59, a portion of the formula determining physician payment rates.

Peripheral Interventions

- CMS has implemented an average reduction of -3.5%(facility) to -5.4%(office) for most of the interventional oncology procedures of interest.
- CMS has updated the per minute payment rates for each clinical staff type that is included in the direct practice expense inputs.

Please see Important Information on Page 7.

**MEDICARE PHYSICIAN FEE SCHEDULE
NATIONAL UNADJUSTED FEE SCHEDULE RATES
COMPARISON 2022 VS 2021**

Physician Fee Schedule (PFS) CY2022 Final Rule Payment Rates Final 2022 PFS Rates Compared to Final 2021								
CPT® Code	Modifier	Description	Final 2022 Facility Payment	Final 2022 vs Final 2021		Final 2022 Office Rate	Final 2022 vs Final 2021	
			\$	\$	%	\$	\$	%
Ablation								
Renal								
50200		Renal biopsy; perc, by trocar or needle	\$124	(\$4)	-3.4%	\$535	(\$34)	-5.9%
50250		Ablation, open, 1 or > renal mass lesion(s), cryosurgical, incl intraop US guidance and monitoring	\$1,194	(\$43)	-3.4%	NA	NA	NA
50542		Laparoscopy, surgical; ablation of renal mass lesion(s), incl intraop US guidance and monitoring	\$1,145	(\$42)	-3.5%	NA	NA	NA
50549		Unlisted laparoscopy procedure, renal	\$0	\$0	NA	\$0	\$0	NA
50592		Ablation, 1 or > renal tumor(s), uni, perc, RF/MW	\$334	(\$12)	-3.4%	\$2,972	(\$314)	-9.6%
50593		Ablation, renal tumor(s), uni, perc, cryotherapy	\$445	(\$17)	-3.7%	\$3,974	(\$440)	-10.0%
53899		Unlisted procedure, urinary system	\$0	\$0	NA	\$0	\$0	NA
Liver								
47000		Biopsy of liver, needle; perc	\$86	(\$4)	-4.1%	\$309	(\$16)	-5.0%
47370		Laparoscopy, surgical, ablation of 1 or > liver tumor(s); RF/MW	\$1,254	(\$36)	-2.8%	NA	NA	NA
47371		Laparoscopy, surgical, ablation of 1 or > liver tumor(s); cryosurgical	\$1,264	(\$35)	-2.7%	NA	NA	NA
47380		Ablation, open, of 1 or > liver tumor(s); RF/MW	\$1,447	(\$41)	-2.7%	NA	NA	NA
47381		Ablation, open, of 1 or > liver tumor(s); cryosurgical	\$1,486	(\$44)	-2.9%	NA	NA	NA
47382		Ablation, 1 or > liver tumor(s), perc, RF/MW	\$718	(\$27)	-3.7%	\$3,839	(\$509)	-11.7%
47383		Ablation, 1 or > liver tumor(s), perc, cryoablation	\$436	(\$15)	-3.3%	\$6,233	(\$649)	-9.4%
47399		Unlisted procedure, liver	\$0	\$0	NA	\$0	\$0	NA
Lung								
32408		Core needle biopsy, lung or mediastinum, perc, incl imaging guidance	\$150	(\$5)	-3.5%	\$891	(\$76)	-7.8%
32994		Ablation, pulmonary tumor(s), incl pleura or chest wall when involved by tumor extension, perc, cryoablation, uni, incl imaging guidance	\$427	(\$15)	-3.5%	\$5,159	(\$499)	-8.8%
32998		Ablation therapy for reduction or eradication of 1 or > pulmonary tumor(s) incl pleura or chest wall when involved by tumor extension, perc, incl imaging guidance, uni; RF/MW	\$427	(\$15)	-3.5%	\$3,259	(\$322)	-9.0%
32999		Unlisted procedure, lungs and pleura	\$0	\$0	NA	\$0	\$0	NA

Please see Important Information on Page 7.

Prostate								
53850		Transurethral destruction of prostate tissue; by MW thermotherapy	\$349	(\$11)	-3.1%	\$1,465	(\$149)	-9.2%
53852		Transurethral destruction of prostate tissue; by RF thermotherapy	\$374	(\$11)	-2.9%	\$1,429	(\$139)	-8.9%
55700		Biopsy, prostate; needle or punch, single or multiple, any approach	\$127	(\$5)	-3.7%	\$243	(\$14)	-5.4%
55873		Cryosurgical ablation of the prostate (incl US guidance and monitoring)	\$751	(\$26)	-3.4%	\$5,980	(\$534)	-8.2%
Breast								
19105		Ablation, cryosurgical, breast fibroadenoma, incl US guidance, ea. fibroadenoma	\$210	(\$7)	-3.1%	\$2,461	(\$331)	-11.8%
19499		Unlisted procedure, breast	\$0	\$0	NA	\$0	\$0	NA
0581T		Ablation, malignant breast tumor(s), perc, cryotherapy, incl imaging guidance, uni	\$0	\$0	NA	\$0	\$0	NA
Nerve								
64620		Dest, neurolytic agent, intercostal nerve	\$175	(\$5)	-3.0%	\$208	(\$7)	-3.4%
64624		Dest, neurolytic agent, genicular nerve branches	\$144	(\$6)	-3.7%	\$397	(\$28)	-6.5%
64630		Dest, neurolytic agent, pudendal nerve	\$192	(\$4)	-1.8%	\$261	(\$1)	-0.2%
64640		Dest, neurolytic agent, oth peripheral nerve/branch	\$117	(\$4)	-3.2%	\$250	(\$12)	-4.7%
0440T		Ablation, perc, cryoablation, incl imaging guidance; upper ext distal/peripheral nerve	\$0	\$0	NA	\$0	\$0	NA
0441T		Ablation, perc, cryoablation, incl imaging guidance; lower ext distal/peripheral nerve	\$0	\$0	NA	\$0	\$0	NA
0442T		Ablation, perc, cryoablation, incl imaging guidance; nerve plexus or other truncal nerve (e.g., brachial plexus, pudendal nerve)	\$0	\$0	NA	\$0	\$0	NA
Ablation Monitoring								
76940	26	US guidance for, and monitoring of, parenchymal tissue ablation	\$98	(\$4)	-4.0%	\$98	(\$4)	-4.0%
77013	26	CT guidance for, and monitoring of, parenchymal tissue ablation	\$180	(\$8)	-4.1%	\$180	(\$8)	-4.1%
77022	26	MR guidance for, and monitoring of, parenchymal tissue ablation	\$200	(\$12)	-5.5%	\$200	(\$12)	-5.5%
Biopsy Guidance								
76942		US guidance for needle placement (e.g., biopsy, aspiration, injection, localization device), RS&I	NA	NA	NA	\$58	(\$1)	-2.0%
76942	26		\$30	(\$1)	-3.7%	\$30	(\$1)	-3.7%
77002		Fluoro guidance for needle placement (e.g., biopsy, aspiration, injection, localization device) (Add-on code)	NA	NA	NA	\$117	(\$2)	-1.5%
77002	26		\$27	(\$1)	-3.7%	\$27	(\$1)	-3.7%
77012		CT guidance for needle placement (e.g., biopsy, aspiration, injection, localization device), RS&I	NA	NA	NA	\$143	(\$8)	-5.5%
77012	26		\$70	(\$3)	-4.2%	\$70	(\$3)	-4.2%
77021		MR guidance for needle placement (e.g., for biopsy, needle aspiration, injection, or placement of localization device), RS&I	NA	NA	NA	\$431	(\$40)	-8.6%
77021	26		\$69	(\$2)	-3.2%	\$69	(\$2)	-3.2%
Other								
0404T		Transcervical uterine fibroid(s) ablation with ultrasound guidance, radiofrequency	\$0	\$0	NA	\$0	\$0	NA

Please see Important Information on Page 7.

20220		Biopsy, bone, trocar, or needle; superficial (e.g., ilium, sternum, spinous process, ribs)	\$85	(\$4)	-4.1%	\$241	(\$16)	-6.3%
20225		Biopsy, bone, trocar, or needle; deep (e.g., vertebral body, femur)	\$127	(\$5)	-3.5%	\$398	(\$26)	-6.2%
20982		Ablation therapy for reduction or eradication of 1 or more bone tumors (e.g., metastasis) including adjacent soft tissue when involved by tumor extension, percutaneous, including imaging guidance when performed; radiofrequency	\$358	(\$13)	-3.6%	\$3,641	(\$379)	-9.4%
38589		Unlisted laparoscopy procedure, lymphatic system	\$0	\$0	NA	\$0	\$0	NA
40820		Destruction of lesion or scar of vestibule of mouth by physical methods (e.g., laser, thermal, cryo, chemical)	\$168	(\$7)	-4.1%	\$265	(\$12)	-4.3%
41530		Submucosal ablation of the tongue base, radiofrequency, 1 or more sites, per session	\$383	(\$14)	-3.5%	\$953	(\$67)	-6.5%
42160		Destruction of lesion, palate, or uvula (thermal, cryo or chemical)	\$142	(\$5)	-3.5%	\$235	(\$9)	-3.8%
49329		Unlisted laparoscopy procedure, abdomen, peritoneum and omentum	\$0	\$0	NA	\$0	\$0	NA
49999		Unlisted procedure, abdomen, peritoneum and omentum	\$0	\$0	NA	\$0	\$0	NA
58353		Endometrial ablation, thermal, without hysteroscopic guidance	\$232	(\$5)	-2.0%	\$976	(\$81)	-7.7%
58563		Hysteroscopy, surgical; with endometrial ablation (e.g., endometrial resection, electrosurgical ablation, thermoablation)	\$244	(\$9)	-3.6%	\$2,229	(\$29)	-1.3%
58674		Laparoscopy, surgical, ablation of uterine fibroid(s) including intraoperative ultrasound guidance and monitoring, radiofrequency	\$813	(\$25)	-3.0%	NA	NA	NA
60699		Unlisted procedure, endocrine system	\$0	\$0	NA	\$0	\$0	NA
76940		Ultrasound guidance for, and monitoring of, parenchymal tissue ablation	NA	NA	NA	\$0	\$0	NA
76940	TC							
76940	26							
77013		Computed tomography guidance for, and monitoring of, parenchymal tissue ablation	NA	NA	NA	\$0	\$0	NA
77013	TC							
77013	26							
77022		Magnetic resonance guidance for, and monitoring of, parenchymal tissue ablation	NA	NA	NA	\$0	\$0	NA
77022	TC							
77022	26							
C2618		Probe/Needle, cryoablation	NA	NA	NA	NA	NA	NA
TheraSphere™								
Simulation (Planning & Nuclear Imaging)								
36245		Selective catheter placement, arterial system; ea. 1st order abdominal, pelvic, or LE artery branch, within a vascular family	\$230	(\$8)	-3.4%	\$1,292	(\$108)	-7.7%
36246		Selective catheter placement, arterial system; init 2nd order abdominal, pelvic, or LE artery branch, within a vascular family	\$248	(\$9)	-3.6%	\$866	(\$46)	-5.0%

Please see Important Information on Page 7.

36247		Selective catheter placement, arterial system; init 3rd order or > selective abdominal, pelvic, or LE artery branch, within a vascular family	\$292	(\$12)	-4.0%	\$1,481	(\$108)	-6.8%
36248		Selective catheter placement, arterial system; add'l 2nd order, 3rd order, and >, abdominal, pelvic, or LE artery branch, within a vascular family (Add-on code to init 2nd or 3rd order vessel)	\$47	(\$3)	-5.1%	\$119	(\$15)	-11.2%
37242		Vascular embolization or occlusion, incl all RS&I, intraprocedural roadmapping, and imaging guidance; arterial, other than hemorrhage or tumor	\$463	(\$18)	-3.7%	\$7,502	(\$568)	-7.0%
75726		Angiography, visceral, selective or supraseductive (w or w/o flush aortogram), RS&I	NA	NA	NA	\$170	(\$11)	-6.1%
75726	TC		NA	NA	NA	\$78	(\$7)	-8.4%
75726	26		\$92	(\$4)	-4.1%	\$92	(\$4)	-4.1%
75774		Angiography, selective, ea. add'l vessel studied after basic examination, RS&I (Add-on code)	NA	NA	NA	\$98	(\$8)	-7.8%
75774	TC		NA	NA	NA	\$52	(\$7)	-11.2%
75774	26		\$46	(\$2)	-3.7%	\$46	(\$2)	-3.7%
77263		Therapeutic Radiology Simulation Tx Planning, Complex	\$165	(\$5)	-2.7%	\$165	(\$5)	-2.7%
77290		Therapeutic Radiology Simulation, Complex	NA	NA	NA	\$456	(\$46)	-9.1%
77290	TC		NA	NA	NA	\$375	(\$44)	-10.6%
77290	26		\$81	(\$1)	-1.7%	\$81	(\$1)	-1.7%
78800		Rp localization tumor/distribution Rp agent, incl vasc flow, planar, 1 area, 1 day	NA	NA	NA	\$242	(\$21)	-8.1%
78800	TC		NA	NA	NA	\$211	(\$20)	-8.7%
78800	26		\$31	(\$1)	-3.7%	\$31	(\$1)	-3.7%
78803		Rp localization tumor/distribution Rp agent, incl vasc flow, (SPECT), 1 area, 1 day	NA	NA	NA	\$365	(\$32)	-8.1%
78803	TC		NA	NA	NA	\$315	(\$30)	-8.8%
78803	26		\$49	(\$2)	-3.7%	\$49	(\$2)	-3.7%
78830		Rp localization tumor/distribution Rp agent, incl vasc flow, (SPECT) w/concurrent CT, 1 area, 1 day	NA	NA	NA	\$461	(\$44)	-8.7%
78830	TC		NA	NA	NA	\$393	(\$41)	-9.4%
78830	26		\$67	(\$3)	-4.2%	\$67	(\$3)	-4.2%
Brachytherapy Clinical Treatment Planning & Dosimetry								
77295		3-dimensional radiotherapy plan, incl dose-volume histograms	NA	NA	NA	\$469	(\$22)	-4.5%
77295	TC		NA	NA	NA	\$248	(\$17)	-6.4%
77295	26		\$221	(\$5)	-2.4%	\$221	(\$5)	-2.4%
77300		Basic dosimetry calc, CADD calc, TDF, NSD, Gap calc, OAF, TIF, NIRSDD calc (req Rx treat phys)	NA	NA	NA	\$64	(\$3)	-4.7%
77300	TC		NA	NA	NA	\$32	(\$2)	-6.6%
77300	26		\$32	(\$1)	-2.7%	\$32	(\$1)	-2.7%
77316		Brachytherapy Isodose Plan, 1-4 Sources, Incl Basic Dosimetry Calc	NA	NA	NA	\$239	\$2	1.0%
77316	TC		NA	NA	NA	\$167	\$4	2.7%
77316	26		\$72	(\$2)	-2.8%	\$72	(\$2)	-2.8%
77317		Brachytherapy Isodose Plan, 5-10 Sources, Incl Basic Dosimetry Calc	NA	NA	NA	\$316	\$5	1.7%
77317	TC		NA	NA	NA	\$221	\$7	3.4%
77317	26		\$95	(\$2)	-2.0%	\$95	(\$2)	-2.0%
77370		Special Medical Radiation Physics Consult	NA	NA	NA	\$130	(\$1)	-0.6%
77470		Special Treatment Procedure	NA	NA	NA	\$134	(\$1)	-0.7%
77470	TC		NA	NA	NA	\$29	\$2	7.7%
77470	26		\$105	(\$3)	-2.8%	\$105	(\$3)	-2.8%
C2699		Brachytherapy source, non-stranded, not otherwise specified, per source	NA	NA	NA	NA	NA	NA

Please see Important Information on Page 7.

TheraSphere™ Administration & Tumor Embolization								
36247		Selective catheter placement, arterial system; init 3rd order or > selective abdominal, pelvic, or LE artery branch, within a vascular family	\$292	(\$12)	-4.0%	\$1,481	(\$108)	-6.8%
36248		Selective catheter placement, arterial system; add'l 2nd order, 3rd order, and >, abdominal, pelvic, or LE artery branch, within a vascular family (Add-on code to init 2nd or 3rd order vessel)	\$47	(\$3)	-5.1%	\$119	(\$15)	-11.2%
37243		Vascular embolization or occlusion, incl all RS&I, intraprocedural roadmapping, and imaging guidance; for tumors, organ ischemia, or infarction	\$543	(\$20)	-3.6%	\$9,050	(\$883)	-8.9%
75726		Angiography, visceral, selective or supraseductive (w or w/o flush aortogram), RS&I	NA	NA	NA	\$170	(\$11)	-6.1%
75726	TC		NA	NA	NA	\$78	(\$7)	-8.4%
75726	26		\$92	(\$4)	-4.1%	\$92	(\$4)	-4.1%
75774		Angiography, selective, ea. add'l vessel studied after basic examination, RS&I (Add-on code)	NA	NA	NA	\$98	(\$8)	-7.8%
75774	TC		NA	NA	NA	\$52	(\$7)	-11.2%
75774	26		\$46	(\$2)	-3.7%	\$46	(\$2)	-3.7%
77778		Interstitial Radiation Source Application, Complex [only when IR is NOT the AU]	NA	NA	NA	\$888	(\$12)	-1.4%
77790		Supervision, handling, loading of radiation source	NA	NA	NA	\$16	\$0	0.6%
77778	TC		NA	NA	NA	\$437	\$0	0.1%
77778	26		\$451	(\$12)	-2.7%	\$451	(\$12)	-2.7%
79445		Radiopharmaceutical Tx (intra-arterial)	NA	NA	NA	\$0	\$0	NA
79445	TC		NA	NA	NA	\$0	\$0	NA
79445	26		\$108	(\$5)	-4.3%	\$108	(\$5)	-4.3%
TheraSphere™ Y-90 Brachytherapy Source								
C2616		Brachytherapy Source, Non-Stranded, Yttrium-90 (per source)	NA	NA	NA	NA	NA	NA
Q3001		Brachytherapy Radioelements, Each	\$0	\$0	NA	\$0	\$0	NA
S2095		Transcatheter Occlusion or Embolization, Tumor Destruction, Percutaneous, Y-90 Microspheres	NA	NA	NA	NA	NA	NA
Embolization (LC BEAD™, LC BEAD LUMI™, BEAD BLOCK™)								
37241		Vascular embolization or occlusion, incl all RS&I, intraprocedural roadmapping, and imaging guidance; venous, other than hemorrhage	\$420	(\$18)	-4.0%	\$4,907	(\$252)	-4.9%
37242		Vascular embolization or occlusion, incl all RS&I, intraprocedural roadmapping, and imaging guidance; arterial, other than hemorrhage or tumor	\$463	(\$18)	-3.7%	\$7,502	(\$568)	-7.0%
37243		Vascular embolization or occlusion, incl all RS&I, intraprocedural roadmapping, and imaging guidance; for tumors, organ ischemia, or infarction	\$543	(\$20)	-3.6%	\$9,050	(\$883)	-8.9%

Please see Important Information on Page 7.

IMPORTANT INFORMATION:

Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules, and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Boston Scientific encourages providers to submit accurate and appropriate claims for services. **It is always the provider's sole responsibility to determine medical necessity, the proper site for delivery of any services, and to submit appropriate codes, charges, and modifiers for services rendered.** It is also always the provider's responsibility to understand and comply with Medicare national coverage determinations (NCD), Medicare local coverage determinations (LCD), and any other coverage requirements established by relevant payers which can be updated frequently. Boston Scientific recommends that you consult with your payers, reimbursement specialists, and/or legal counsel regarding coding, coverage, and reimbursement matters.

Boston Scientific does not promote the use of its products outside its FDA-approved label. Payer policies will vary and should be verified before treatment for limitations on diagnosis, coding, or site of service requirements. All trademarks are the property of their respective owners.

This coding information may include codes for procedures for which Boston Scientific currently offers no cleared or approved products. In those instances, such codes have been included solely in the interest of providing users with comprehensive coding information and are not intended to promote the use of any Boston Scientific products for which they are not cleared or approved. The Health Care Provider (HCP) is solely responsible for selecting the site of service and treatment modalities appropriate for the patient based on medically appropriate needs of that patient and the independent medical judgment of the HCP.

CPT © Copyright 2020 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. All trademarks are the property of their respective owners.

**Boston
Scientific**

Advancing science for life™

Peripheral Interventions

One Scimed Place

Maple Grove, MN 55311-1566

www.bostonscientific.com

© 2021 Boston Scientific Corporation
or its affiliates. All rights reserved.

PI.Reimbursement@bsci.com